Article
Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
Thoracic cancer - 1 Feb 2021
Miyashita Yosuke, Ko Ryo, Shimada Naoko, Mitsuishi Yoichiro, Miura Keita, Matsumoto Naohisa, Asao Tetsuhiko, Shukuya Takehito, Shibayama Rina, Koyama Ryo, Takahashi Kazuhisa
Abstract excerpt
BACKGROUND: There are few studies that directly compare the effects of osimertinib on patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase inhibitors (TKIs). METHODS: We retrospectively reviewed clinical data from the medical records of consecutive patients with advanced NSCLC who had developed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.